Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? MS ID#: NEURIMMINFL/ 2018/019398

Published: 21 June 2020| Version 1 | DOI: 10.17632/ht5s9cc845.1
Hadas Stiebel-Kalish


In this study we tested the hypothesis that timing of intravenous (IVMP) affects visual outcome in a cohort of aquaporin4 (AQP4)-IgG and MOG-IgG positive patients with ON by analyzing the effect of the number of days until treatment commenced with the best-corrected visual acuity at three months. The results provides Class III evidence that hyperacute treatment of AQP4 and MOG-ON with IVMP increases the chance for excellent visual recovery (20/20 vision) and that even a greater than 7 day delay in treatment is associated with a higher risk for poor visual recovery.



Humboldt Universitat zu Berlin Wirtschaftswissenschaftliche Fakultat, Charite Universitatsmedizin Berlin Institut fur Rechtsmedizin, Rabin Medical Center, Charite Universitatsmedizin Berlin NeuroCure Klinisches Forschungszentrum, Universitatsklinikum Freiburg, Technion Israel Institute of Technology Ruth and Bruce Rappaport Faculty of Medicine, Tel Aviv University


Clinical Outcomes Research